American Statistical Association
An increasing number of clinical trials in cancer, HIV/AIDS, and other disease areas are designed as non-inferiority trials, in which the goal is to show that the effect of an experimental therapy is not worse by more than a pre-specified margin than the standard therapy. A particularly difficult issue in these studies is that sources of "noise" that can arise during the trial, such as non-compliance and other protocol deviations, can obscure treatment differences and lead to anti-conservative results. In this talk, I will provide an overview of ongoing methodological challenges in non-inferiority trials, propose several approaches for addressing the impact of protocol deviations, and demonstrate the importance of conducting sensitivity analyses to assess robustness of results.
|Date:||Wednesday, December 7, 2016|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan Kettering Cancer Center
Department of Epidemiology and Biostatistics
485 Lexington Avenue
(Between 46th & 47th Streets)
2nd Floor Conference Room B
New York, New York
**Outside visitors please email Tania at firstname.lastname@example.org for building access.
You must be on the security list to enter the floor.